Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
193.90
+0.50 (+0.26%)
Official Closing Price
Updated: 4:10 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
65
66
Next >
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Wednesday Morning
January 24, 2024
Via
Investor Brand Network
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
January 23, 2024
Via
Benzinga
AbbVie Inc Chart Analysis
January 23, 2024
Technical analysis of the stock chart for ABBV.
Via
Talk Markets
Breaking Down AbbVie: 7 Analysts Share Their Views
January 23, 2024
Via
Benzinga
2 Genius Safe Stocks to Buy for 2024 and Beyond
January 23, 2024
These companies have considerable profits and tried-and-true dividends in common.
Via
The Motley Fool
7 Dividend Aristocrats That Will Pay You for Years to Come
January 22, 2024
If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024.
Via
InvestorPlace
AbbVie's Options Frenzy: What You Need to Know
January 12, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
January 09, 2024
Via
Benzinga
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
Via
Benzinga
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
January 21, 2024
These stocks may help you win in 2024 -- no matter what the market does.
Via
The Motley Fool
S&P 500 Shatters Records: The Top-Performing Stocks In January 2024
January 19, 2024
2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Pfizer, Autodesk, AbbVie And More: CNBC's 'Final Trades'
January 19, 2024
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund (NYSE: XLV)
Via
Benzinga
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'
January 18, 2024
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc.
Via
Benzinga
2 Beaten-Down Stocks to Buy Hand Over Fist This Year
January 18, 2024
Don't give up on these stocks too soon.
Via
The Motley Fool
Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
January 17, 2024
Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation.
Via
Benzinga
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
January 16, 2024
On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named Crown Castle Inc.
Via
Benzinga
Better Growth Stock: Abbott vs. AbbVie
January 16, 2024
These healthcare giants also offer investors the promise of increasing passive income.
Via
The Motley Fool
Here's the Average Amount Investors Have in Stocks by Age 40 and Which Stocks I Recommend Today
January 14, 2024
Curious as to how your portfolio stacks up? Take a look.
Via
The Motley Fool
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
January 11, 2024
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.
Via
Benzinga
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
January 11, 2024
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing...
Via
Benzinga
Exposures
Product Safety
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
January 11, 2024
Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
January 10, 2024
Via
Benzinga
3 Simple Tricks That Every Investor Should Use (but Most Don't)
January 09, 2024
Having a few tricks up your sleeve can increase your returns over time.
Via
The Motley Fool
Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
January 08, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted.
Via
Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond
January 07, 2024
You should do your best to avoid making similar mistakes too.
Via
The Motley Fool
Is AbbVie Stock a Buy Now?
January 07, 2024
The company is grappling with losing Humira's patent protection in 2023.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
24 Top Dividend Stocks to Buy and Hold in 2024
January 07, 2024
These stocks could deliver positive gains in the new year -- but the real money-making opportunities are over the next decade and beyond.
Via
The Motley Fool
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
January 06, 2024
There's more than meets the eye with all three of these dividend stocks.
Via
The Motley Fool
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.